Articles

What if the AI future being sold to markets rests on claims that cannot survive scrutiny? From superintelligence to mass job loss, the loudest promises around generative AI begin to look less like foresight than hype dressed up as inevitability.

Affordability of electricity and concerns about fossil fuel pollution, water resources, and job loss, have driven a rebellion against data centers that is both grassroots and bipartisan. It’s time for cleaner, faster and cheaper solutions.

Europe’s social media crackdown is less about “speech wars” than a long-overdue attempt to price the public damage created by large platforms.

Europe’s revamped fiscal rules promise discipline and stability, but Italy’s numbers tell a different story. Once realistic multipliers and hysteresis are built in, consolidation pushes debt up, growth down, and recessionary pressure outwards across the eurozone, hardly a recipe for sustainability.

AI was sold as a tool to broaden the marketplace of ideas. Instead, a handful of platforms now control how truth travels, shaping what we see, starving journalism, and locking new AI rivals out of the data democracy needs to survive.

The new $100,000 H-1B fee tacitly acknowledges what early policy architects signaled: expanding temporary tech visas can depress domestic wages. By bringing the fully loaded cost of a new H1B hire closer to what the local market would require to recruit and retain comparable talent, it narrows the wedge between visa-enabled staffing and hiring Americans at market rates.

Here’s the breakdown on what’s really driving America’s runaway drug prices — and whether any of the current plans stand a chance to lower your pharmacy bill.

Contrary to what many economic models suggest, salaries aren’t constantly recalibrated based on skills or technology. They follow the economy and politics—and common sense: hire when needed, promote from within, and slow hiring when budgets tighten.

Two economists who have studied Intel warn that Trump’s move to take a stake in the company amounts to flashy optics, incoherent strategy, and a creeping politicization of economic policy.

Has the Inflation Reduction Act hindered pharmaceutical innovation? Evidence shows that the pharma industry can strategically manage disruptive change.